Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Superior temporal gyrus thickness correlates with cognitive performance in multiple sclerosis.
Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033.
Automated patient-specific optimization of three-dimensional double-inversion recovery magnetic resonance imaging.
Levels of plasma sulfatides C18:0 and C24:1 correlate with disease status in Relapsing-Remitting Multiple Sclerosis.
Pathological correlates of magnetic resonance imaging texture heterogeneity in multiple sclerosis.
Pathophysiology of immune-mediated demyelinating neuropathies - Part II: Neurology.
A new model for primary-progressive multiple sclerosis?
Progressive resistance therapy is not the best way to rehabilitate deficits due to multiple sclerosis: Yes.
Interpreting therapeutic effect in multiple sclerosis via MRI contrast enhancing lesions: now you see them, now you don't.
Relationship between Working Hours and Power of Attention, Memory, Fatigue, Depression and Self-Efficacy One Year after Diagnosis of Clinically Isolated Syndrome and Relapsing Remitting Multiple Sclerosis.
Mode of action and clinical studies with alemtuzumab.
The STAR Study: A Real-World, International, Observational Study of the Safety and Tolerability of, and Adherence to, Serum-Free Subcutaneous Interferon β-1a in Patients With Relapsing Multiple Sclerosis.
Two-photon imaging of remyelination of spinal cord axons by engrafted neural precursor cells in a viral model of multiple sclerosis.
Disruption of structural and functional networks in long-standing multiple sclerosis.
Neurobehavioral burden of multiple sclerosis with nanotheranostics.
Acute disseminated encephalomyelitis presenting as pyrexia of unknown origin.
Painful tonic spasms and brainstem involvement in a patient with neuromyelitis optica spectrum disorder.
A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis.
Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica.
The prevalence of familial multiple sclerosis in saskatoon, Saskatchewan.
Concomitant analysis of arterial, venous, and CSF flows using phase-contrast MRI: a quantitative comparison between MS patients and healthy controls.
Longitudinally Extensive Transverse Myelitis With and Without Aquaporin 4 Antibodies.
[Vitamin D and neurology.]
Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis.
Multiple sclerosis: Lessons from molecular neuropathology.
Pages
« first
‹ previous
…
332
333
334
335
336
337
338
339
340
…
next ›
last »